20
Participants
Start Date
November 12, 2015
Primary Completion Date
February 19, 2018
Study Completion Date
September 12, 2018
Carfilzomib
Given IV
Laboratory Biomarker Analysis
Correlative studies
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Moffitt Cancer Center, Tampa
Ohio State University Comprehensive Cancer Center, Columbus
Fred Hutch/University of Washington Cancer Consortium, Seattle
National Cancer Institute (NCI)
NIH
Fred Hutchinson Cancer Center
OTHER